Market open
Soleno Therapeutics/$SLNO
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Soleno Therapeutics
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Ticker
$SLNO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
92
Website
SLNO Metrics
BasicAdvanced
$3.3B
-
-$4.38
-1.69
-
Price and volume
Market cap
$3.3B
Beta
-1.69
52-week high
$74.00
52-week low
$36.61
Average daily volume
1.5M
Financial strength
Current ratio
15.677
Quick ratio
15.546
Long term debt to equity
21.337
Total debt to equity
21.552
Interest coverage (TTM)
-798.39%
Management effectiveness
Return on assets (TTM)
-45.06%
Return on equity (TTM)
-87.35%
Valuation
Price to book
13.45
Price to tangible book (TTM)
13.84
Price to free cash flow (TTM)
-41.826
Growth
Earnings per share change (TTM)
85.15%
3-year earnings per share growth (CAGR)
-9.02%
SLNO News
AllArticlesVideos
Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder
Benzinga·1 week ago
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
GlobeNewsWire·1 week ago
Soleno Therapeutics to Participate in Upcoming February Investor Conferences
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Soleno Therapeutics stock?
Soleno Therapeutics (SLNO) has a market cap of $3.3B as of April 04, 2025.
What is the P/E ratio for Soleno Therapeutics stock?
The price to earnings (P/E) ratio for Soleno Therapeutics (SLNO) stock is 0 as of April 04, 2025.
Does Soleno Therapeutics stock pay dividends?
No, Soleno Therapeutics (SLNO) stock does not pay dividends to its shareholders as of April 04, 2025.
When is the next Soleno Therapeutics dividend payment date?
Soleno Therapeutics (SLNO) stock does not pay dividends to its shareholders.
What is the beta indicator for Soleno Therapeutics?
Soleno Therapeutics (SLNO) has a beta rating of -1.69. This means that it has an inverse relation to market volatility.